Why the study?
Do lipoprotein subfraction measurements improve clinical assessment of CVD risk beyond standard lipid risk markers?
Do lipoprotein subfraction measurements improve clinical assessment of CVD risk beyond standard lipid risk markers?
Refined analyses of lipoprotein subspecies may improve CVD risk evaluation and identify therapeutic targets, though current evidence is inconclusive.
Should not yet inform clinical CVD risk assessment; leaves open whether subspecies analyses improve evaluation or targets.
Although there is as yet inconclusive evidence as to the extent to which LDL and HDL subfraction measurements improve clinical assessment of CVD risk beyond standard lipid risk markers, recent studies suggest that more refined analyses of lipoprotein subspecies may lead to further improvements in CVD risk evaluation and particularly in identification of appropriate targets for therapeutic intervention in individual patients.
No takes yet. Share an insight, caveat, or question.
Ronald M. Krauss (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: